NRx Pharmaceuticals announced that its first clinical trial site has been contracted and that first dosing of patients is expected in early 2023. This Phase 3 clinical trial of NRX-101 is for the treatment of Severe Bipolar Depression with Acute Suicidal Ideation and Behavior, or SBD-ASIB, a lethal condition that currently takes the lives of thousands of Americans each year. NRX-101 is the first investigational medicine to target this condition, for which the only currently approved treatment is Electroconvulsive Therapy.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NRXP:
